Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 361 AL 375

The role of glial cells in Alzheimer disease: potential therapeutic implications

Lopategui Cabezas I, Herrera Batista A, Pentón Rol G.

Neurologia. 2014 Jun;29(5):305-9. doi: 10.1016/j.nrl.2012.10.006. Epub 2012 Dec 14.

Changes in gait variability with anti-dementia drugs: a systematic review and meta-analysis

Beauchet O, Launay CP, Allali G, Annweiler C.

CNS Drugs. 2014 Jun;28(6):513-8. doi: 10.1007/s40263-014-0170-6.

Alzheimer disease and type 2 diabetes mellitus: the link to tyrosine hydroxylase and probable nutritional strategies

Aliev G, Shahida K, Gan SH, Firoz C, Khan A, Abuzenadah AM, Kamal W, Kamal MA, Tan Y, Qu X, Reale M.

CNS Neurol Disord Drug Targets. 2014 Apr;13(3):467-77. doi: 10.2174/18715273113126660153.

An 85-year old male with levodopa-responsive parkinsonism followed by dementia and supranuclear ophthalmoplegia caused by alzheimer-type pathology without Lewy bodies

Kasahata N, Hagiwara M, Kato H, Nakamura A, Uchihara T.

J Alzheimers Dis. 2014;39(3):471-6. doi: 10.3233/JAD-131508.

Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases

Hölscher C.

Biochem Soc Trans. 2014 Apr;42(2):593-9. doi: 10.1042/BST20140016.

The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis

Killin LO, Russ TC, Starr JM, Abrahams S, Della Sala S.

BMJ Open. 2014 Apr 7;4(4):e004083. doi: 10.1136/bmjopen-2013-004083.

Insulin resistance and gray matter volume in neurodegenerative disease

Morris JK, Vidoni ED, Perea RD, Rada R, Johnson DK, Lyons K, Pahwa R, Burns JM, Honea RA.

Neuroscience. 2014 Jun 13;270:139-47. doi: 10.1016/j.neuroscience.2014.04.006. Epub 2014 Apr 13.

Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders

Forlenza OV, De-Paula VJ, Diniz BS.

ACS Chem Neurosci. 2014 Jun 18;5(6):443-50. doi: 10.1021/cn5000309. Epub 2014 May 6.

Novel drug delivery systems for releasing growth factors to the CNS: focus on Alzheimer's and Parkinson's diseases

Herran E, Igartua M, Pedraz JL, Hernandez RM.

Mini Rev Med Chem. 2014;14(7):557-66. doi: 10.2174/1389557514666140622205058.

Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies

Broadstock M, Ballard C, Corbett A.

Expert Opin Pharmacother. 2014 Sep;15(13):1797-810. doi: 10.1517/14656566.2014.936848. Epub 2014 Jul 3.

Radioligand imaging of α4β2* nicotinic acetylcholine receptors in Alzheimer's disease and Parkinson's disease

Meyer PM, Tiepolt S, Barthel H, Hesse S, Sabri O.

Q J Nucl Med Mol Imaging. 2014 Dec;58(4):376-86. Epub 2014 Nov 11.

Donepezil-induced myoclonus in a patient with Alzheimer disease

Bougea A, Gerakoulis S, Anagnostou E, Paraskevas G, Kapaki E, Kararizou E.

Ann Pharmacother. 2014 Dec;48(12):1659-61. doi: 10.1177/1060028014550334. Epub 2014 Sep 8.

Donepezil-induced cervical dystonia in Alzheimer's disease: a case report and literature review of dystonia due to cholinesterase inhibitors

Ikeda K, Yanagihashi M, Sawada M, Hanashiro S, Kawabe K, Iwasaki Y.

Intern Med. 2014;53(9):1007-10. doi: 10.2169/internalmedicine.53.1857. Epub 2014 May 1.

Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation

Kamal MA, Priyamvada S, Anbazhagan AN, Jabir NR, Tabrez S, Greig NH.

CNS Neurol Disord Drug Targets. 2014 Mar;13(2):338-46. doi: 10.2174/18715273113126660137.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias